Post COVID-19 Mucormycosis-The Horizon

Area of Science:

• Medical Mycology
• Infectious Diseases
• Otolaryngology

Background:

• Acute Invasive Fungal Rhinosinusitis (AIFR), commonly known as mucormycosis, is a rare but severe opportunistic infection.
• AIFR has seen increased incidence in patients recovering from COVID-19, particularly after the second wave.
• Risk factors include uncontrolled diabetes mellitus and corticosteroid use, which are often associated with severe COVID-19 cases.

Purpose of the Study:

• To retrospectively evaluate the occurrence and characteristics of Acute Invasive Fungal Rhinosinusitis (Mucormycosis) in patients following COVID-19 infection.
• To identify common clinical presentations, risk factors, and treatment outcomes in this patient cohort.
• To assess the survival rate associated with timely diagnosis and management of AIFR in post-COVID-19 individuals.

Main Methods:

• A descriptive, retrospective study involving 110 patients diagnosed with AIFR after recent COVID-19 infection.
• Histopathological confirmation of mucormycosis was performed for all included patients.
• Patients underwent surgical debridement and received antifungal agents; RT PCR for COVID-19 influenced surgical timing.

Main Results:

• The study included 110 patients with a mean age of 48.42 years; 88.2% had diabetes mellitus.
• Common involvements included sino-nasal (57.9%) and orbital (48.5%). Key symptoms were periorbital edema and headache.
• The overall survival rate was high at 95.32% following surgical and antifungal treatment.

Conclusions:

• Acute Invasive Fungal Rhinosinusitis is a life-threatening infection more prevalent in moderate to severe COVID-19 patients.
• Uncontrolled diabetes and corticosteroid use are significant risk factors.
• Prompt diagnosis and aggressive management, including surgery and antifungals, are crucial for improving patient survival rates.